Camille Mathé

Camille Mathé

Auto-generated profile, based on publicly available information

Camille Mathé

Inserm, Nantes Université, CHU de Nantes, Center for Research in Transplantation and Translational Immunology CR2TI, UMR 1064, ITUN, Nantes, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EMEmmanuel Montassier
Emmanuel Montassier
GAGabriel A. Al-Ghalith
Gabriel A. Al-Ghalith
CMCamille Mathé
Camille Mathé
QBQuentin Le Bastard
Quentin Le Bastard
VDVenceslas Douillard
Venceslas Douillard
Laureline BerthelotLaureline Berthelot
Laureline Berthelot
Because of a loss-of-function mutation in the GGTA1 gene, humans are unable to synthetize α1,3-Galactose (Gal) decorated glycans and develop high levels of circulating anti-α1,3-Galactose antibodies (anti-Gal Abs). Anti-Gal Abs have been identified as a major obstacle of organ xenotransplantation and play a role in several host-pathogen relationships including potential susceptibility to infection. Anti-Gal Abs are supposed to stem from immunization against the gut microbiota, an assumption derived from the observation that some pathogens display α1,3-Gal and that antibiotic treatment decreases the level of anti-Gal. However, there is little information to date concerning the microorganisms producing α1,3-Gal in the human gut microbiome. Here, available α1,3-Galactosyltransferase (GT) gene sequences from gut bacteria were selectively quantified for the first time in the gut microbiome shotgun sequences of 163 adult individuals from three published population-based metagenomics analyses. We showed that most of the gut microbiome of adult individuals contained a small set of bacteria bearing α1,3-GT genes. These bacteria belong mainly to the Enterobacteriaceae family, including Escherichia coli, but also to Pasteurellaceae genera, Haemophilus influenza and Lactobacillus species. α1,3-Gal antigens and α1,3-GT activity were detected in healthy stools of individuals exhibiting α1,3-GT bacterial gene sequences in their shotgun data.

1 May 2020 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
AVAmélie Vallino
Amélie Vallino
ASAmélie Dos Santos
Amélie Dos Santos
CMCamille V. Mathé
Camille V. Mathé
AGAlexandra Garcia
Alexandra Garcia
JMJérémy Morille
Jérémy Morille
Laureline BerthelotLaureline Berthelot
Laureline Berthelot
MS is a chronic inflammatory disease of the CNS involving T cell and B cell responses. Recently, several studies have described modifications of specific bacterium abundances of gut microbiota in patients with remitting-relapsing MS compared with healthy individuals (see for review 1). This was often associated with an increase in Akkermansia muciniphila bacteria. In experimental autoimmune encephalomyelitis, transfer of gut microbiota from patients with MS to mice induced proinflammatory responses and exacerbation of the disease, whereas microbiota from healthy volunteers (HVs) were less inflammatory. 2,3 Because bacteria in the gut modulate immune responses, we assessed the antibody production against A muciniphila in patients with MS. In CSF, levels of anti-A muciniphila immunoglobulin G (IgG) were increased in patients with MS compared with controls, whereas no difference was found for levels of IgG against Escherichia coli, Fusobacterium necrophorum, Acinetobacter baumannii, Prevotella melaninogenica, and Bacteroides fragilis.

27 January 2026 in Kidney360
Verified
Journal Article
Open access
Laureline BerthelotLaureline Berthelot
Laureline Berthelot
Nicolas DegauqueNicolas Degauque
Nicolas Degauque
LCLaura Cappelier
Laura Cappelier
NSNicolas Sailliet
Nicolas Sailliet
CMCamille Mathé
Camille Mathé
Sophie BrouardSophie Brouard
Sophie Brouard
Key Points: Tolerant patients of kidney graft exhibit higher IgA production than other kidney transplanted patients without modification for IgG. IgA-expressing B cells from tolerant patients expressed granzyme B and exert regulatory functions through granzyme B production. Background: Tolerant kidney transplant recipients without immunosuppression have a high frequency of circulating granzyme B (GZMB)–expressing regulatory B cells (Breg). Because the precursors of these Bregs remain unknown and IgA-secreting B cells have been shown to have regulatory properties in different situations, we investigated the association between IgA- and GZMB-expressing B cells in a case-control study. Methods: Forty-five healthy volunteers and 31 kidney transplant recipients with either stable graft function under immunosuppression ( n =10), antibody-mediated rejection ( n =7), or tolerant patients (TOL; n =14) were included. Serum immunoglobulin concentrations as glycosylation were measured by ELISA; forms of IgA were examined by Western blot. Bregs were analyzed by single-cell RNA sequencing and multiparameter spectral flow cytometry. Their function was assessed in cocultured with T cells. Results: Serum IgA concentration was elevated in TOL compared with other transplanted patients, especially the noninflammatory IgA1 subclass, without changes in IgA size or glycosylation. Single-cell transcriptomic analysis revealed higher IgA gene expression in GZMB expressing B cells and conversely higher GZMB gene expression in IgA-expressing B cells. Phenotyping analysis by spectral multiparameter flow cytometry showed that IgA+ B cells were memory B cells, and that IgA+ B cells from TOL tended to express more GZMB compared with antibody-mediated rejection patients. In functional assays, IgA+ B cells exhibited high regulatory functions that were partially prevented by the presence of GZMB inhibitor. Conclusions: These data show a strong association between IgA+ and GZMB+ Bregs, particularly in tolerant kidney transplant recipients with higher GZMB and IgA expression and greater suppressive properties. Clinical Trial registry name and registration number: NCT02900040.